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Estrogens play an important role in the initiation and promo-
tion of estrogen receptor– and/or progesterone-positive breast 
cancers; patients with hormone receptor–positive breast cancers 
are candidates for endocrine therapy. Aromatase (cytochrome 
P450 (CYP) 19) is the rate-limiting enzyme in the biosynthesis 
of estrogens from androgens.1 Letrozole is a nonsteroidal tria-
zole derivative, one of the third-generation potent and selective 
competitive inhibitors of aromatase,2 which effectively depletes 
plasma and tissue estrogen.3,4 Letrozole is now widely used as 
adjuvant therapy in postmenopausal women with hormone 
receptor–positive early-stage breast cancer and for extended 
therapy in patients with early-stage breast cancer who have 
already received 5 years of adjuvant tamoxifen therapy.5,6 Despite 
its proven efficacy, letrozole does not benefit all patients, and a 
significant proportion of patients are at increased risk for serious 
long-term adverse effects, notably musculoskeletal symptoms,7 
bone loss, and fractures.6 The mechanisms underlying inter-
patient variability in letrozole response remain unknown, and 
there are therefore no biomarkers that help identify women who 
will derive benefit from letrozole treatment.
One factor that appears to contribute to variable drug response 
in breast cancer therapy is variability in drug metabolism, as has 
been shown with tamoxifen.8–10 Letrozole is cleared predomi-
nantly by metabolism through the CYP enzyme system to phar-
macologically inactive carbinol (4,4′-methanol-bisbenzonitrile) 
and probably to ketone metabolites.11 The exact pattern of these 
metabolic pathways is currently unclear. The carbinol metabolite 
is rapidly excreted, primarily in urine, in the form of glucuronide 
conjugates.12 Evidence exists that letrozole pharmacokinetics 
varies widely among patients;11 this, in turn, may contribute to 
differences in biochemical and clinical responses to this drug. It 
is therefore important to identify mechanisms and factors that 
are responsible for the interindividual variability in the pharma-
cokinetics of letrozole.
Given that letrozole is metabolized mainly by the CYP system, 
the pharmacokinetics of the drug is likely to be controlled by 
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The associations between plasma letrozole concentrations and CYP2A6 and CYP3A5 genetic variants were tested in the 
exemestane and letrozole pharmacogenomics (elph) trial. elph is a multicenter, open-label prospective clinical trial in 
women randomly assigned (n ≈ 250 in each arm) to receive 2 years of treatment with either oral letrozole (2.5 mg/day) or 
oral exemestane (25 mg/day). Cyp2a6 and Cyp3a showed effects on letrozole metabolism in vitro. Dna samples were 
genotyped for variants in the CYP2A6 and CYP3A5 genes. plasma letrozole concentrations showed high interpatient 
variability (>10-fold) and were associated significantly with CYP2A6 genotypes (P < 0.0001), body mass index (Bmi)  
(P < 0.0001), and age (P = 0.0035). however, CYP3A5 genotypes showed no association with plasma letrozole 
concentrations. These data suggest that Cyp2a6 is the principal clearance mechanism for letrozole in vivo. Cyp2a6 
metabolic status, along with Bmi and age, may serve as a biomarker of the efficacy of letrozole treatment or a predictor of 
adverse effects.
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the activity of the CYPs involved. However, the specific CYPs 
that catalyze letrozole metabolism have not been fully charac-
terized. In an in vitro study, letrozole was shown to be a com-
petitive inhibitor of CYP2A6, with marginal effects on other 
CYPs tested;13 these findings are consistent with a recent in 
vitro report suggesting that CYP2A6 might mediate the high-
affinity enzymatic component for letrozole metabolism.14 Also, 
information provided in the product label implicates CYP3A 
and CYP2A6 in letrozole metabolism.11 However, there are no 
published data that systematically address the contribution of 
these or other enzymes in vitro. More importantly, the value of 
these in vitro data in predicting in vivo letrozole exposure has 
not been studied.
The purpose of the present study was therefore to identify 
the pathways of letrozole metabolism and the CYPs involved 
in the process, using in vitro human liver cellular fractions and 
expressed CYPs. We next tested the hypothesis that genetic vari-
ants involved in letrozole metabolism in vitro also predict letro-
zole concentrations in plasma in patients with breast cancer.
Results
In vitro studies
Incubation of 10 µmol/l letrozole with human liver micro-
somes (HLMs) and cofactors resulted in the formation of 
one main metabolite that was identified as 4,4′-methanol-
bisbenzonitrile. No other metabolites of letrozole, including 
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Figure 1 Inhibition of the metabolism of letrozole to 4,4′-methanol-bisbenzonitrile in human liver microsomes (HLMs) by isoform specific inhibitors.  
(a) Letrozole (10 µmol/l) was incubated with HLMs (0.5 mg/ml) and cofactors with and without the following inhibitors: furafylline (20 µmol/l, CYP1A2), pilocarpine 
(50 µmol/l, CYP2A6), thioTEPA (50 µmol/l, CYP2B6), ticlopidine (5 µmol/l, CYP2B6, and CYP2C19), sulfaphenazole (25 µmol/l, CYP2C9), omeprazole (5 µmol/l, 
CYP2C19), quinidine (1 µmol/l, CYP2D6), diethyldithiocarbamate (50 µmol/l, CYP2E1), and ketoconazole (1 µmol/l, CYP3A); (b) IC50 values were determined by 
incubating letrozole with HLMs and cofactors with and without multiple inhibitor concentrations. The data represent either mean values ± SD in a or average of 
duplicate incubations in b. CYP, cytochrome P450.
Patients (Pts) enrolled in the ELPH trial
(N = 503)
Pts randomized
to letrozole
(N = 252)
Pts randomized
to exmestane
(N = 248)
Pts crossed over
to letrozole
(N = 54)
Dropped out or
crossed over before
1 month (N = 11)
Dropped out before 1 month
or crossed over after April
2010  (N = 11)
Letrozole plasma
concentration
(N = 241)
Total letrozole
plasma concentation
(N = 284)
Genotyped for
CYP2A6 (N = 261)
CYP3A5 (N = 270)
No DNA available
CYP2A6 (N = 23)
CYP3A5 (N = 14)
Letrozole plasma
concentration
(N = 43)
Pts withdrew or
not randomized
(N = 3)
Figure 2 Flow diagram illustrating enrollment of patients (Pts) and analyses of samples. ELPH, Exemestane and Letrozole Pharmacogenomics.
CliniCal pharmaCology & TherapeuTiCs | VOLUME 90 NUMBER 5 | NOVEMBER 2011 695
articles
the ketone metabolite mentioned in the product label,11 were 
identified after incubation of letrozole with HLMs (or expressed 
enzymes) and cofactors using high-performance liquid chro-
matography (HPLC) with ultraviolet or fluorescent detection 
and by liquid chromatography–tandem mass spectrometry 
approaches (see Supplementary Methods online). Subsequent 
experiments showed that the formation rate of 4,4′-methanol- 
bisbenzonitrile (i) was characterized by a Hill equation: 
Km = 37.5 ± 1.2 µmol/l, Vmax = 18.6 ± 14.0 pmol/min/mg pro-
tein, and the Hill coefficient = 1.80 ± 0.42; (ii) showed ∼26-fold 
variability among 21 HLMs and was significantly correlated 
with CYP3A (Spearman r = 0.72; P = 0.0002) and CYP2A6 
(r = 0.45; P = 0.04); (iii) was inhibited by the CYP3A inhibitor 
ketoconazole (IC50 = 0.28µmol/l) and by the CYP2A6 inhibitor 
pilocarpine (IC50 = 8.2µmol/l) (Figure 1); and (iv) was formed 
by CYP2A6>CYP3A4 (and, to some extent, CYP2C19 and 
CYP2D6).
Clinical studies
Distribution of letrozole plasma concentrations. Plasma samples 
were available from 241 of the patients who had initially 
been randomized to the letrozole arm (n = 252) (Figure 2). 
Additional plasma samples were obtained from 43 patients 
who had initially been randomized to the exemestane arm but 
crossed over to letrozole before the 1-month (n = 7), 3-month 
(n = 35), or 6-month (n = 1) blood sample draw (Figure 2). The 
distribution of plasma concentrations of letrozole in the total 
cohort (N = 284) was characterized by large interpatient vari-
ability (median, 88.4 ng/ml; range, 0–349.2ng/ml) (Figure 3). 
In four of the patients, plasma letrozole concentrations were 
not detectable. Compliance with treatment regimens was not 
formally assessed in this trial, and the information obtained 
from patients’ self-reports in the charts indicates that two of 
the patients took their last letrozole dose within the 3 h prior 
to the blood draw, whereas there was no record of the tim-
ing with respect to the other two patients. The samples were 
assayed twice to rule out errors. The plasma letrozole concen-
tration remained highly variable, with a median of 89.7 ng/ml 
(range: 28.4–349.2ng/ml; 12.3-fold difference) even after the 
data for the four aforementioned patients were excluded. The 
inset in Figure 3 illustrates frequency distribution and probit 
analysis of letrozole concentrations, which was skewed toward 
high concentrations.
Associations between plasma letrozole concentrations and demo-
graphic variables. The demographic characteristics of the patients 
are shown in Supplementary Table S1 online. As shown in 
Figure 4 and Table 1, plasma letrozole concentrations were 
positively correlated with age (Pearson r = 0.17; P = 0.0035) and 
negatively correlated with body mass index (BMI) (r = −0.26; 
P < 0.0001). Linear regression analysis revealed that age (R2 = 
0.03; P = 0.0035) and BMI (R2 = 0.068; P = 8.6 × 10−6) were 
associated with plasma letrozole concentrations (Figure 4; and 
Table 1). The sample size was too small (Asian, 6; black, 25) 
to test for associations with race (Supplementary Table S1 
online).
Associations between CYP2A6 genotype groups and plasma letrozole 
concentrations. DNA samples from 235 patients who had ini-
tially been randomized to receive letrozole, and from 40 other 
patients who had crossed over from the exemestane arm to the 
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Figure 5 Plasma letrozole concentrations in individual CYP2A6 genotypes. 
On the basis of genotype-predicted phenotypes, patients were grouped into 
normal (n = 200; *1/*1), intermediate (IM) (n = 40; *1/*9 and *1/*12), and slow 
(n = 21) metabolizer groups.
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letrozole arm, were genotyped for CYP2A6 variants (total n = 
275). In 261 patients, data related to both genotype and plasma 
letrozole concentrations were available (Figure 2). Most of the 
subjects in this study were white (Supplementary Table S1 
online). Data from 259 subjects were used in the final analyses. 
No significant differences in demographic characteristics were 
observed among the three genotype groups (Supplementary 
Table S1 online). The frequencies of the CYP2A6 genotypes, 
depicted in Figure 5, were in Hardy–Weinberg equilibrium. 
The genotype groups were categorized as normal, intermedi-
ate, or slow metabolizer groups (see Methods section) on the 
basis of genotype-predicted phenotype as shown by nico-
tine metabolism.15,16 The median (minimum to maximum) 
plasma letrozole concentrations in normal, intermediate, 
and slow metabolizers of CYP2A6 were 81.2 (0–217.5), 112.4 
(52.7–1256.9), and 152.1 (50.0–268.6) ng/ml, respectively. 
Statistically significant differences in letrozole concentrations 
were observed among the three genotype groups (P < 0.0001; 
Kruskal–Wallis test) (Figure 6a). Post hoc analysis revealed sig-
nificantly higher plasma letrozole concentrations in slow and 
intermediate metabolizers relative to those in normal metabo-
lizers (P < 0.0001 for each) (Figure 6a). Large interindividual 
variability was seen within each genotype (Figure 6a). Simple 
linear regression analysis (Table 1) revealed that CYP2A6 
genetic variation was significantly associated with plasma 
letrozole concentration (adjusted R2 = 0.229; P = 2.49 × 10−16) 
(Table 1).
The data shown in Figure 5 reveal that the phenotype pre-
dicted by CYP2A6*1/*26 and CYP2A6*1/*35 genotypes was 
consistent with normal metabolizers of letrozole rather than 
slow metabolizers, whereas CYP2A6*12 was associated more 
with slow metabolizers than with intermediate metabolizers. 
These data are in contrast to the CYP2A6 genotype–phenotype 
associations reported on the basis of nicotine metabolism.15,16 
Given the ambiguity of the predictions regarding phenotype, 
and in order to ensure that no bias was introduced into esti-
mates of the strength of genotype–phenotype associations on 
this account, additional analyses were performed after the two 
genotypes (CYP2A6*1/*26 and CYP2A6*1/*35; n = 1 each) were 
excluded from the analysis, whereas data from CYP2A6*1/*12 
(n = 11) were analyzed on the assumption that they related to 
slow metabolizers.Supplementary Table S2 online shows that 
the data from both analyses were essentially similar to those 
listed in Table 1, although the strength of the association was 
slightly stronger when the genotype-predicted phenotype was 
on the basis of letrozole concentrations (R2 = 0.265) than on the 
basis of nicotine metabolism (R2 = 0.229).
CYP3A5 genotypes and their associations with plasma letrozole con-
centrations. A total of 288 DNA samples were genotyped for 
CYP3A5 variants (*3, *6, and *7). Letrozole concentrations and 
genotypes were available for only 270 of the patient samples. 
When the data were analyzed using the same approach as with 
CYP2A6 genotype-predicted phenotype (normal, intermedi-
ate, and slow metabolizers), no significant associations were 
observed (one-way analysis of variance; P = 0.16) among the 
three groups. The r2 derived from linear regression was 0.0048 
(P = 0.256). Given that most of the patients studied were white, 
it is not surprising that the number of patients with the *1/*1 
genotype was very small (n = 7) (Supplementary Table S1 
online). We found no statistically significant differences in 
letrozole concentrations between CYP3A5 expressors (n = 42: 
*1/*1, n = 7; *1/*3, n = 31; *1/*6, n = 3; and n = 1, *1/*7) and 
nonexpressors (n = 237: 3/*3, n = 228; *3/*6, n = 3; *3/*7, n = 4; 
*6/*6, n = 1; and *6/*7, n = 1) (Figure 6b; Table 1).
Multivariate analyses. In the multivariate analyses, signifi-
cant associations were noted between plasma letrozole 
 concentrations and CYP2A6 genotype (P < 2 × 10−16), BMI 
table 1 Associations of letrozole plasma concentrations with 
CYP2A6 and CYP3A5 genotypes and demographic variables
independent variable adjusted r2 β Coefficient (se) T value P value
simple variate (simple linear regression) analysis
CYP2A6 gene score
 Normal
 Intermediate
 Slow
0.229 −32.963 (3.76) −8.77 2.49 × 10−16
CYP3A5 gene score
 Expressor
 Nonexpressor
0.002 −5.66 (7.72) −0.73 0.47
Age 0.0299 0.85 (0.29) 2.95 0.0035
BMI 0.068 −1.7261 (0.38) −4.53 0.00000861
multivariate analysis
CYP2A6 gene score 
 Normal 
 Intermediate 
 Slow
−33.57 (3.55) −9.45 <2 × 10−16
Age 0.59 (0.246) 2.4 0.0172
BMI −1.82 (0.327) −5.57 0.000000064
Age+BMI+CYP2A6 
genotype
0.323 <2.2 × 10−16
All CYP2A6 genotype data were included and analyzed after the genotype-predicted 
phenotypes were categorized as normal, intermediate, or slow metabolizer according 
to nicotine metabolism (see Methods section for details). CYP3A5 expressors carry one 
or two functional alleles, and CYP3A5 nonexpressors carry two nonfunctional alleles.
BMI, body mass index.
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(6.4 × 10−8), and age (P = 0.017). The incorporation of age and 
BMI in the multiple regression analyses significantly improved 
the overall predictive value of CYP2A6 genotype; the R2 value 
of 0.229 in the model containing CYP2A6 genetic markers 
alone rose to an adjusted value of 0.323 in the model con-
taining CYP2A6 genotypes plus demographic variables. The 
absolute difference in the variation in letrozole concentrations 
attributable to age and BMI was ∼9.4% (Table 1).
DisCussion
In the present study, CYP2A6 and CYP3A enzymes were iden-
tified as the principal catalysts in the metabolism of letrozole 
into 4,4′-methanol-bisbenzonitrile in vitro. The genes coding 
for these enzymes were therefore selected for focused study of 
genotype–phenotype associations in a large-scale clinical trial 
in postmenopausal women with breast cancer. Letrozole con-
centrations exhibited considerable interpatient variability in this 
cohort of patients. This variability can be explained to a large 
extent by CYP2A6 genetic variations and to a smaller extent by 
demographic factors, notably BMI and age; together, all these 
(CYP2A6 variations plus demographic factors) explain ∼32.3% 
of the interpatient variability. CYP3A5 genotype had no evi-
dent association with plasma letrozole concentrations in vivo. 
These data impart important information that may be applied 
to individualize letrozole therapy. In addition, they suggest that 
CYP2A6 may be involved in the principal clearance mechanism 
of letrozole in vivo.
Plasma letrozole concentrations varied more than 10-fold 
among patients with breast cancer who had quantifiable lev-
els of letrozole. We estimate that ~23% of the letrozole vari-
ability is attributable to CYP2A6 genetic variation. These in 
vivo data broadly concur with our in vitro findings showing 
the participation of CYP2A6 in letrozole metabolism (present 
data and ref. 13). Other investigators have also reported that 
CYP2A6 and CYP3A represent the high- and low-affinity com-
ponents, respectively, in the formation of the carbinol metabo-
lite of letrozole.14 Although the results of these in vitro studies 
point toward a role for CYP2A6 in the in vivo metabolism of 
letrozole, it remains less clear whether this in vivo effect can 
be fully predicted from in vitro studies evaluating formation 
of 4,4′-methanol-bisbenzonitrile. According to the informa-
tion provided in the product label, CYP2A6 is the sole cata-
lyst in the metabolism of letrozole to a ketone metabolite, 
whereas CYP2A6 and CYP3A are involved in the formation 
of 4,4′-methanol-bisbenzonitrile.11 As proposed in our previ-
ous study, these two metabolites might be sequentially formed 
from letrozole, with the ketone being formed first, probably by 
CYP2A6, and subsequently being converted to 4,4′-methanol-
bisbenzonitrile by CYP2A6 and CYP3A.13 If the latter model 
holds true, CYP2A6 could be the rate-limiting step in letrozole 
metabolism, as shown in our in vivo results; under this condi-
tion, assessing 4,4′-methanol-bisbenzonitrile alone would sub-
stantially underestimate the quantitative in vivo role of CYP2A6, 
given that there appears to be significant participation from 
CYP3A in the formation of this metabolite in vitro (present 
data and ref. 14). Unfortunately, this suggestion, although 
plausible, remains speculative because no ketone metabolite 
standard was available to us and repeated attempts to identify 
the ketone metabolite in our in vitro and in vivo studies did not 
succeed. Regardless of the specific mechanisms involved, the 
findings of this study provide in vivo evidence that CYP2A6 
is involved in the main clearance mechanism of letrozole and 
that this drug can now be added to the list of the few clinically 
important substrates of CYP2A6. The data suggest that letrozole 
may serve as a safe, alternative in vivo probe of CYP2A6 activity. 
Unfortunately, metabolite data were not obtained in this study to 
enable a proper evaluation of this suggestion. Attempts to meas-
ure concentrations of letrozole metabolites in plasma were not 
successful because these were below the limit of quantification 
of the assay, even after enzymatic hydrolysis by β-glucuronidase. 
This is not surprising because the quantity of letrozole metabo-
lite in plasma is expected to be minimal given that letrozole has 
a very long elimination half-life (90–120 h) with very low oral 
clearance (1.2 l/h at steady state)12 and that any metabolites that 
are slowly produced undergo efficient phase II conjugation and 
rapid elimination through the kidney. Although a high abun-
dance of conjugated letrozole metabolite is expected in urine,12 
urine samples were not collected in these patients, and therefore 
these metabolic ratios could not be calculated. This study was 
not designed to address the utility of letrozole as a probe for 
CYP2A6. Formal pharmacokinetic studies, including determi-
nation of metabolite(s) in urine and comparison with established 
probes, are needed to validate the suggestion that letrozole can 
serve as an alternative probe for CYP2A6 in vivo.
Our data show that BMI and age are independent predictors of 
plasma letrozole concentrations. The inclusion of age and BMI 
in the multivariate model significantly improved the overall pre-
dictive value from 22.9% in a model containing only CYP2A6 
genetic markers to 32.3% in the model containing CYP2A6 
genetic markers plus demographic factors, yielding an absolute 
difference of ∼9.4% of the variation in letrozole concentration as 
being attributable to age and BMI. The relatively lower plasma 
concentrations of letrozole in the peripheral compartment (i.e., 
plasma) may reflect the fact that letrozole is a highly lipophilic 
drug with a large volume of distribution (183 l)12 and that the 
volume of distribution increases with increasing BMI. The study 
finding that letrozole concentrations increase with increasing 
age concurs with previous reports showing an effect of age on 
CYP2A6 activity.17,18 One study reported no effect of age on 
letrozole exposure12; however, this result was possibly due to 
the small size of the study cohort.
Interestingly, ∼68% of the variability in letrozole concentra-
tions remains unaccounted for. First, although a relatively com-
prehensive genotyping was performed, it is possible that other 
(rare) CYP2A6 variants that were not considered in this study, 
including gain-in-function alleles,19 may contribute to this vari-
ability. Second, drug interactions may influence CYP2A6 activ-
ity, given that patients with breast cancer often take other drugs 
concomitantly.9 Medication data were carefully collected in this 
study population, but their impact on letrozole concentrations 
was not assessed because the inhibitors and inducers of CYP2A6 
are less characterized than those that influence other CYPs 
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(http://medicine.iupui.edu/clinpharm/ddis). Third, although 
our data show little effect of CYP3A5 genotypes on letrozole 
concentrations, the possibility of the involvement of CYP3A4 
in letrozole metabolism in vivo cannot be excluded. Finally, the 
possibility that other unidentified metabolic pathways may con-
tribute cannot be fully ruled out, although this is unlikely given 
that metabolites other than the ketone and carbinole metabo-
lites account for <5% of the dose in mass-balance studies.11,12 
Although female sex is an independent predictor of increased 
CYP2A6 activity,20 this was not an issue in this study because 
all the patients were postmenopausal women.
We realize that genotype–phenotype associations may be prone 
to be false positives in the absence of replication, particularly 
when the analysis deals with one of many secondary end points 
of the study, as in this instance. Consequently, the lack of external 
replication is a limitation of this study. In addition, our suggestion 
that CYP2A6 might be involved in the main clearing mechanism 
for letrozole in vivo cannot be confirmed in the absence of metab-
olite data; such data could have provided further information on 
whether there is an inverse relationship between letrozole and 
metabolite levels and whether the metabolic ratios are related to 
the CYP2A6 status. Despite these limitations, there are findings 
that constitute compelling evidence implicating CYP2A6 as the 
dominant clearance mechanism of letrozole in vivo. These find-
ings include: the robust association between CYP2A6 genetic var-
iations and plasma letrozole concentrations (the present study); 
the available in vitro data supporting the hypothesis that CYP2A6 
is involved in letrozole metabolism (the present study as well as 
refs. 11,13,14); and the fact that the functional consequences of 
CYP2A6 variants, assessed from plasma letrozole concentrations, 
cosegregate for the most part with those assessed from nicotine 
metabolic status,15,16,21 supporting the proposition that nicotine 
and letrozole are metabolized by the same enzyme, i.e., CYP2A6. 
Therefore, we believe that the findings of our study have impor-
tant implications. First, if letrozole plasma concentrations and/
or CYP2A6 genetic variants can predict letrozole efficacy and 
adverse effects, they may eventually be utilized to individual-
ize breast cancer therapy using letrozole. In the Exemestane and 
Letrozole Pharmacogenomics (ELPH) trial, several biomarkers of 
efficacy and side effects of letrozole have been studied. Analyses 
of the trial data are ongoing to test the associations between 
letrozole concentrations and/or CYP2A6 genetic variations with 
regard to a large number of phenotypic outcomes. The results of 
these analyses may also have relevance to other settings in which 
letrozole is widely used, especially as an inducer of ovulation in 
women with infertility.22 Second, given that CYP2A6 appears to 
be involved in the dominant clearance mechanism of letrozole 
in vivo, letrozole may serve as an alternative in vivo marker of 
CYP2A6 activity in postmenopausal women and in men. Third, 
because the letrozole metabolic pattern appears to diverge from 
nicotine metabolism with respect to a few CYP2A6 variants (*12, 
*26, and *35), consistent with a previous report for variants such 
as CYP2A6*17 between coumarin and nicotine,23 letrozole may 
be a valuable novel tool to resolve the issue of potential substrate-
dependent effects of CYPA6 genetic variants, particularly those 
that lead to structural changes. In conclusion, steady-state plasma 
concentrations of letrozole exhibit high interpatient variability in 
postmenopausal women with breast cancer, and this variability 
is partially explained by CYP2A6 metabolic status.
MethoDs
In vitro studies 
Kinetic, correlation,24 and inhibition13,24,25 analyses in HLMs and experi-
ments in expressed CYPs were performed to identify letrozole metab-
olites and the specific CYPs involved (for details see Supplementary 
Methods online).
Clinical studies: the elPh trial
Study patients. Postmenopausal women (18 years and older) with stage 
0–III hormone receptor–positive breast cancer who were being started 
on aromatase inhibitor therapy, either “up-front” or after 1–5 years of 
tamoxifen treatment, were eligible. Eligible patients were recruited from 
August 2005 through July 2009 at the following COBRA member institu-
tions: Indiana University Cancer Center, Sidney Kimmel Comprehensive 
Cancer Center at Johns Hopkins University, and the University of 
Michigan Comprehensive Cancer Center. Inclusion and exclusion criteria 
for participating in this study are detailed elsewhere.26 All indicated treat-
ments (surgery, radiation therapy, and chemotherapy) for breast cancer 
were completed prior to study enrollment. The protocol was approved by 
the institutional review boards of all three participating study sites, and all 
the enrolled patients provided written informed consent. The clinical trial 
was reviewed on a biannual basis by an independent data and safety mon-
itoring committee. The trial is registered at http://www.clinicaltrials.gov 
(trial identifier NCT00228956).
Study design. The ELPH trial is a multicenter, open-label, randomized, pro-
spective clinical trial. Patients were randomly assigned to receive either 
exemestane 25 mg orally daily or letrozole 2.5 mg orally daily for 2 years. 
DNA samples, plasma samples, and multiple phenotypic outcomes were 
prospectively collected at baseline and at multiple time points (up to 24 
months) after drug administration for pharmacogenetic correlative analy-
ses. The primary objective of the study was to correlate changes in breast 
density with aromatase (CYP19) genetic variation. The secondary objec-
tives included testing for associations between various phenotypes (e.g., 
bone density and bone turnover metabolites, serum lipids, estrogen con-
centrations, hot flashes, quality-of-life measures, and drug concentrations) 
and variants in candidate genes. This report addresses a secondary hypoth-
esis that genetic variants in drug-metabolizing enzymes predict letrozole 
concentrations. Briefly, blood samples (10 ml) were obtained at baseline 
and at 1, 3, 6, and 12 months after letrozole initiation. Plasma was separated 
from blood samples by centrifugation at 2,060g and stored at −80 °C until 
analysis. Plasma letrozole concentrations were determined from samples 
collected 1, 3, or 6 months after initiating letrozole. Plasma samples from 
patients who were randomized to the letrozole arm, and who stayed in this 
arm for at least 1 month, were analyzed. No plasma samples were available 
for those who discontinued the study or crossed over to the exemestane 
group before the 1-month blood draw. In addition, plasma samples from 
patients who were initially randomized to exemestane and were switched 
later to letrozole were also assayed for letrozole concentrations.
DNA samples. Genotyping was performed using genomic DNA extracted 
from whole blood using the QIAamp DNA Blood Maxi Kit–Spin Protocol 
in accordance with the manufacturer’s instructions (Qiagen, Valencia, 
CA). DNA samples from subjects who had initially been randomized to 
the letrozole arm, and from those who had crossed over from exemestane 
to letrozole, were analyzed.
CYP2A6 genotyping. All DNA samples were genotyped for CYP2A6 *2, 
*4E (detects *4A/D, C, and E), *9, and *12, and African Americans were 
additionally genotyped for *17, *20, *23, *24, *25, *26, *27, and *35 and 
Asians for *7, *8, and *10, using methods previously described.15,21,27 
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Subjects were then divided into three categories on the basis of previously 
published associations between CYP2A6 genotypes and nicotine metabo-
lism.21 Individuals with one copy of the decrease-of-function alleles (*9 
and *12 ) were categorized as intermediate metabolizers; those with two 
copies of the decrease-of-function alleles or one or two copies of loss-
of-function alleles (CYP2A6*2, *4, *7, *10, *17, *20, *23, *24, *25,*26, 
*27, and *35) or one decrease-of-function allele together with one loss-
of-function allele as slow metabolizers; and those without these genetic 
variants as normal metabolizers (*1/*1).
Despite the fact that individuals with alleles *26 and *35 have previ-
ously been categorized as slow metabolizers of nicotine,15,16 our study 
showed these alleles to be associated with relatively lower letrozole con-
centrations (Figure 5). The *1/*12 genotype, which codes for an interme-
diate nicotine metabolizer,21 was consistent with other loss-of-function 
alleles when assessed from the viewpoint of letrozole concentrations 
(Figure 5). Therefore, in addition to the analyses according to catego-
rizations based on the effects of the genotypes on nicotine metabolism, 
secondary analyses were performed after recategorization of the *1/*12 
(n = 11) genotype as slow metabolizer. The *1/*26 (n = 1) and *1/*35 
(n = 1) genotypes were excluded from these analyses because of uncer-
tainty regarding genotype-predicted phenotype and small sample sizes. 
In effect, regarding the genotype-predicted phenotypes for the alleles *12, 
*26, and *35, there were differences depending on whether nicotine21 or 
letrozole (the present study) was used as a substrate. If these results could 
be further confirmed, a novel categorization of substrate-dependent allele 
functionality and genotypic effect could be proposed on the basis of the 
results of our study.
CYP3A5 genotyping. DNA samples were genotyped for the alleles *3, 
*6, and *7 using allelic-discrimination TaqMan SNP genotyping assays 
(Applied Biosystems, Foster City, CA).
HPLC assay. A new HPLC assay was developed to measure letrozole 
concentrations in plasma. To 100 μl of plasma, 50 μl of 1µg/ml internal 
standard and 25 μl of methanol were added; this was vortex-mixed and 
centrifuged at 14,000 rpm for 5 min in an Eppendorf model 5415C cen-
trifuge (Brinkmann Instruments, Westbury, NY). The supernatant was 
extracted with 0.5 ml of 1mol/l NaOH/glycine buffer (pH = 11.3) and 6 ml 
ethyl acetate. The organic phase was evaporated to dryness. The residue 
was reconstituted with 150 μl of mobile phase, and 50 μl was injected into 
the HPLC system. The separation system included a Zorbax SB-C18 col-
umn (3.5 μm particle size, 150 × 4.6 mm; Phenomenex, Torrance, CA), a 
Nova-Pak C18 guard column (Waters, Milford, MA)(4-μm particle size), 
and a mobile phase consisting of 30% acetonitrile and 70% 10mmol/l 
KH2PO4 (adjusted to pH = 6.5), with a flow rate of 1 ml/min. The col-
umn elute was monitored by fluorescent detector (excitation, 230 nm; 
emission, 295 nm) (letrozole) or by ultraviolet detection set at 234 nm 
(internal standard). Letrozole was quantified using the ratio of peak area 
of letrozole to the peak area of internal standard, and calibration curves 
were constructed using known letrozole concentrations spiked to blank 
plasma. The limit of quantification of this assay was 7 ng/ml, with interday 
and intraday coefficients of variation of <6.5% and <10%, respectively.
Data and statistical analyses. In vitro data are provided in Supplementary 
Methods online.
Continuous variables were summarized groupwise using descriptive 
statistics. The observed and expected frequencies of alleles and genotypes 
within populations were tested for deviation from Hardy–Weinberg 
equilibrium, using the χ2-test. Differences in letrozole concentrations 
among the three different genotype groups of CYP2A6 were analyzed 
using nonparametric analysis of variance (Kruskal–Wallis test), with 
Dunnett’s multiple-comparison post-test. Simple linear regression analy-
sis was used to analyze the correlations between letrozole concentrations 
and genetic (CYP2A6, CYP3A5) as well as demographic variables (age, 
race, BMI). The contributions of these variables to the overall intersub-
ject variability of plasma letrozole concentrations were subsequently 
tested using multiple linear regression analyses. In particular, CYP2A6 
was coded in the categories normal, intermediate, and slow metaboliz-
ers. CYP3A5 was coded as expressors (1) and nonexpressors (0). Sta-
tistical analyses were performed using the statistics software packages 
SPSS, version 16.0 (SPSS, Chicago, IL) and GraphPad Prism (version 
5.02, San Diego, CA). All tests were two sided. P < 0.05 was considered 
statistically significant.
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